Second Quarter 2008 Corporate Highlights: - European marketing application under review for NGX-4010 in peripheral
neuropathic pain - NGX-4010 NDA for PHN on track for submission in second half of 2008
- IND submitted and opened for NGX-1998 liquid capsaicin formulation
- Phase 1 clinical trial of NGX-1998 initiated - Journal Neurology published positive Phase 3 data on NGX-4010 in HIV-DSP
SAN MATEO, Calif., Aug. 13 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for the quarter ended June 30, 2008.
In the second quarter of 2008, the Company continued on its path toward potential commercialization of its lead product candidate, NGX-4010, a dermal capsaicin patch designed for the treatment of certain neuropathic pain conditions. On the U.S. regulatory front, the Company has been preparing a New Drug Application (NDA) to support marketing approval of NGX-4010 for the treatment of post-herpetic neuralgia (PHN), and is on track to submit an NDA to the U.S. Food and Drug Administration (FDA) later this year.
The Company continues to pursue the European approval of its Marketing Authorization Application (MAA) for NGX-4010 in neuropathic pain, which the European Medicines Agency (EMEA) accepted for review in September 2007. In September of 2008, the Company, with the EMEA's agreement, plans to submit responses to the regulatory agency's Day 120 questions, which are part of the review process for the MAA.
In addition to focusing on regulatory activities for NGX-4010,
NeurogesX has made significant progress with
|SOURCE NeurogesX, Inc.|
Copyright©2008 PR Newswire.
All rights reserved